{"filings":[{"id":98973,"accession_number":"0000805928-26-000051","cik":805928,"company_name":"Axogen, Inc.","ticker":"AXGN","form_type":"8-K","filed_at":"2026-04-28T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Axogen Q1 revenue $61.5M (+27% YoY); raises FY 2026 revenue guidance to at least $270M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $61.5M, up 26.6% YoY; gross margin expanded to 75.2% from 71.9%.","GAAP net loss $19.6M ($0.38/share); adjusted net income $4.1M ($0.07/share) vs adjusted net loss $0.9M in Q1 2025.","Raises full-year 2026 revenue guidance to at least 20% growth or $270M; expects gross margin 74%-76% and positive free cash flow.","Closed upsized public offering netting $133.3M; used $69.7M to repay Oberland loan; cash & investments rose to $103.6M.","Received positive coverage decisions from Cigna and Elevance Health; CMS new Level 3 Nerve Procedure Code boosts Avance reimbursement."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.38,"consensus_revenue_estimate":null,"consensus_revenue_actual":61457000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2120199958.4981904,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114718,"accession_number":"0000805928-26-000028","cik":805928,"company_name":"Axogen, Inc.","ticker":"AXGN","form_type":"8-K","filed_at":"2026-02-24T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Axogen Q4 revenue $59.9M (+21%); FY2025 $225.2M; guides 2026 growth >=18%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $59.9M (+21.3% YoY); net loss $13.2M ($0.28/sh); adjusted net income $3.5M ($0.07/sh).","FY2025 revenue $225.2M (+20.2% YoY); adjusted net income $14.4M ($0.29/sh); adjusted EBITDA $27.9M.","FDA approved Avance BLA on Dec 3, 2025; CMS new Level 3 code raises Avance facility reimbursement 40% to $8,965.","Closed upsized public offering of 4.6M shares for $133.3M net; $69.7M used to repay Oberland loan facility.","2026 guidance: revenue at least $265.7M (+18% YoY); gross margin 74%-76%; expects positive free cash flow."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":225208000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2120199958.4981904,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114717,"accession_number":"0000805928-26-000026","cik":805928,"company_name":"Axogen, Inc.","ticker":"AXGN","form_type":"8-K","filed_at":"2026-01-23T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Axogen prices $124M public offering at $31/share; proceeds to pay off $69.7M credit facility","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Pricing of upsized 4M share offering at $31.00/share for gross proceeds of ~$124M (assuming no over-allotment).","Net proceeds used primarily to repay ~$69.7M term loan with Oberland Capital, terminating that credit facility.","Underwriters granted 30-day option to purchase up to an additional 600K shares (~$18.6M).","Offering expected to close on January 23, 2026; Wells Fargo and Mizuho are lead book-running managers.","Remaining net proceeds for working capital, capital expenditures, and general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2120199958.4981904,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114716,"accession_number":"0000805928-26-000004","cik":805928,"company_name":"Axogen, Inc.","ticker":"AXGN","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Axogen reports preliminary Q4 revenue $59.9M (+21.3% YoY); full-year $225.2M (+20.2%); FDA BLA approval for Avance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 revenue ~$59.9M (+21.3% YoY); full-year 2025 revenue ~$225.2M (+20.2% YoY).","Gross margin expected above 74% for Q4 and FY 2025; includes ~$1.9M one-time costs related to Avance BLA approval, 67% non-cash.","Cash, equivalents, restricted cash, and investments ~$45.5M at Dec 31, 2025, up ~$6.0M from end of 2024.","FDA approved Biologics License Application for Avance (acellular nerve allograft) on Dec 3, 2025.","Growth driven by commercial strategy targeting Extremities and OMF-Head & Neck, and increased Resensation penetration."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":225208000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2120199958.4981904,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131096,"accession_number":"0000805928-25-000146","cik":805928,"company_name":"Axogen, Inc.","ticker":"AXGN","form_type":"8-K","filed_at":"2025-12-05T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Axogen raises CFO Hartley's base salary 7%, bonus target to 60%, adds 2-year non-compete","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Lindsey Hartley's annual base salary increased by 7% effective January 1, 2026.","Target bonus opportunity raised from 50% to 60% of base salary under annual incentive program.","Entered Amended Agreement with two-year post-employment non-competition covenant.","New compensation and agreement effective January 1, 2026 and December 5, 2025 respectively."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":2120199958.4981904,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131095,"accession_number":"0000805928-25-000140","cik":805928,"company_name":"Axogen, Inc.","ticker":"AXGN","form_type":"8-K","filed_at":"2025-12-04T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Axogen receives FDA approval of BLA for Avance nerve allograft under Accelerated Approval pathway","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved Biologics License Application for Avance (acellular nerve allograft) for sensory, mixed, motor nerve discontinuities in adults and pediatric patients 1 month+.","Indications for sensory gaps >25mm and mixed/motor gaps approved under Accelerated Approval pathway; continued approval depends on confirmatory studies.","Commercial launch of licensed Avance expected early Q2 2026; product remains available under current tissue framework until then.","CEO Michael Dale says approval strengthens regulatory footing and confirms Avance as safe, pure, potent therapeutic option."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2120199958.4981904,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131094,"accession_number":"0000805928-25-000128","cik":805928,"company_name":"Axogen, Inc.","ticker":"AXGN","form_type":"8-K","filed_at":"2025-10-29T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Axogen Q3 revenue $60.1M (+23.5% YoY); raises FY revenue guidance to at least $222.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income of $0.7M ($0.01 EPS) vs net loss of $1.9M in Q3 2024; adjusted EPS $0.12 vs $0.07.","Gross margin improved to 76.6% from 74.9% YoY; adjusted EBITDA $9.2M vs $6.5M.","Raised full-year revenue guidance to at least $222.8M (≥19% growth); gross margin reaffirmed 73-75%.","FDA PDUFA for Avance Nerve Graft BLA extended to Dec 5, 2025; AAHS and ASRM issued position statements recognizing nerve allografts.","Added 18.1M covered lives in 2025; commercial payer coverage now over 64%."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":165304000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2120199958.4981904,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147682,"accession_number":"0000805928-25-000112","cik":805928,"company_name":"Axogen, Inc.","ticker":"AXGN","form_type":"8-K","filed_at":"2025-08-25T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"FDA extends PDUFA date for Axogen's Avance Nerve Graft BLA to Dec 5, 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA deemed Axogen's August 22 submission a Major Amendment, extending PDUFA goal date by three months to Dec 5, 2025.","FDA now anticipates providing product labeling feedback in November 2025.","Submission included substantial new manufacturing and facility data not previously reviewed by the Agency."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2120199958.4981904,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147681,"accession_number":"0000805928-25-000104","cik":805928,"company_name":"Axogen, Inc.","ticker":"AXGN","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Axogen Q2 2025 revenue $56.7M (+18.3% YoY); raises FY guidance to $219M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $56.7M (+18.3% YoY); net income $0.6M ($0.01 EPS) vs loss of $1.9M ($0.04) year ago.","Adjusted EPS $0.12 vs $0.05 YoY; adjusted EBITDA $9.3M vs $5.6M; gross margin 74.2% up from 73.8%.","Raised FY25 revenue guidance to at least 17% growth, or $219M; reiterates gross margin 73-75% and net cash flow positive.","FDA accepted BLA for Avance Nerve Graft; PDUFA date Sept 5, 2025; pre-licensing inspection and regulatory milestones completed."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":105222000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2120199958.4981904,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166356,"accession_number":"0000805928-25-000095","cik":805928,"company_name":"Axogen, Inc.","ticker":"AXGN","form_type":"8-K","filed_at":"2025-06-20T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Axogen shareholders approve all five proposals at 2025 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected eight directors to one-year terms; all received >26.7M votes for.","Ratified Deloitte & Touche as independent auditor for FY2025; 37.0M for, 36K against.","Approved advisory say-on-pay resolution with 28.7M for, 3.2M against.","Approved amendment to 2019 LTI Plan increasing authorized shares from 10.5M to 13.4M.","Adopted 1-year frequency for future say-on-pay votes with 31.1M votes for 1 year."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.15,"market_cap_usd":2120199958.4981904,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166355,"accession_number":"0000805928-25-000062","cik":805928,"company_name":"Axogen, Inc.","ticker":"AXGN","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Axogen Q1 revenue $48.6M (+17.4% YoY); appoints Lindsey Hartley as CFO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $48.6M, up 17.4% YoY; net loss $3.8M ($0.08/share) vs $6.6M loss in Q1 2024.","Adjusted net loss $0.9M ($0.02/share) vs $2.7M loss; adjusted EBITDA $2.9M vs $1.0M prior year.","Gross margin 71.9% down from 78.8% due to product costs and inventory write-offs; cash $28.1M.","CFO Nir Naor steps down May 11; Lindsey Hartley appointed effective May 12; salary $440k, target bonus 50%.","FY guidance maintained: revenue growth 15-17%, gross margin 73-75%, net cash flow positive."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":48560000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2120199958.4981904,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166354,"accession_number":"0000805928-25-000053","cik":805928,"company_name":"Axogen, Inc.","ticker":"AXGN","form_type":"8-K","filed_at":"2025-04-07T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Axogen anticipates minimal impact from new U.S. tariffs on operations","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["President Trump announced broad tariff plan on April 2, 2025.","Axogen states vast majority of sales are domestic; manufacturing also domestic.","Imported materials costs are minimal, limiting tariff exposure.","Company expects no material impact from tariffs or retaliatory actions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":2120199958.4981904,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183795,"accession_number":"0000805928-25-000024","cik":805928,"company_name":"Axogen, Inc.","ticker":"AXGN","form_type":"8-K","filed_at":"2025-03-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Axogen posts updated corporate presentation on investor website","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Updated investor presentation dated March 4, 2025 posted to Axogen's website.","Presentation may be used in conversations with analysts and investors.","No specific financial or operational details from the presentation disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":2120199958.4981904,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183794,"accession_number":"0000805928-25-000010","cik":805928,"company_name":"Axogen, Inc.","ticker":"AXGN","form_type":"8-K","filed_at":"2025-02-25T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Axogen Q4 2024 revenue up 15.1% to $49.4M; reports first quarterly net income of $0.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $49.4M (+15.1% YoY); gross margin 76.1% vs 74.6%.","Q4 net income $0.4M ($0.01 EPS) vs net loss $3.9M prior year; adjusted net income $3.5M ($0.07 EPS).","Full-year 2024 revenue $187.3M (+17.8% YoY); adjusted EBITDA $19.8M vs -$1.1M in 2023.","FDA accepted BLA for Avance Nerve Graft; PDUFA goal date Sept 5, 2025; anticipates approval.","2025 guidance: revenue growth 15-17%, gross margin 73-75%, expects positive net cash flow."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":187338000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2120199958.4981904,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183793,"accession_number":"0000805928-25-000006","cik":805928,"company_name":"Axogen, Inc.","ticker":"AXGN","form_type":"8-K","filed_at":"2025-01-10T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Axogen reports Q4 2024 revenue $49.4M (+15.1% YoY); FY 2024 revenue $187.3M (+17.8%)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 revenue expected $49.4M, up 15.1% YoY; full-year 2024 revenue $187.3M, up 17.8%.","Full-year gross margin expected above 75.5%; cash and investments $39.5M, up $2.5M from 2023.","Growth driven by commercial execution in Extremities, OMF-Head & Neck, and Resensation adoption.","Investor Day scheduled for March 4, 2025 to discuss strategic priorities."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":187338000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2120199958.4981904,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200394,"accession_number":"0000805928-24-000135","cik":805928,"company_name":"Axogen, Inc.","ticker":"AXGN","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Axogen Q3 revenue $48.6M (+18% YoY), adjusted net income $3.1M; BLA accepted by FDA","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $48.6M (+17.9% YoY); gross margin 74.9% vs 76.8% in prior year.","Net loss $1.9M ($0.04/shr) vs $4.1M ($0.10/shr); adjusted net income $3.1M ($0.07/shr).","Adjusted EBITDA $6.5M vs $2.4M in Q3 2023; cash $30.5M at quarter end.","FDA accepted BLA for Avance Nerve Graft under standard review; PDUFA date Sept 5, 2025; no advisory committee planned.","2024 revenue guidance reaffirmed $182M-$186M; expects high end of gross margin range and cumulative net cash flow positive."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":137933000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2120199958.4981904,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216424,"accession_number":"0000805928-24-000127","cik":805928,"company_name":"Axogen, Inc.","ticker":"AXGN","form_type":"8-K","filed_at":"2024-09-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Axogen completes BLA submission to FDA for Avance Nerve Graft; priority review requested","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA submission for Avance Nerve Graft completed under rolling review process on Sept. 6, 2024.","Company requested priority review; if granted, review timeline could be 6 months vs. standard 10 months.","Avance previously received RMAT designation from FDA under 21st Century Cures Act.","FDA expected to notify acceptance and confirm review timeline within approximately 60 days.","Company on track for FDA approvability determination between April and September 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2120199958.4981904,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216423,"accession_number":"0001193125-24-197821","cik":805928,"company_name":"Axogen, Inc.","ticker":"AXGN","form_type":"8-K","filed_at":"2024-08-09T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Axogen appoints Michael Dale as CEO; Karen Zaderej steps down, remains advisory","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael Dale becomes CEO, President, and Director effective August 9, 2024; Karen Zaderej exits CEO role.","Paul Thomas appointed Chair of the Board, effective August 9, 2024; he joined the Board in 2020.","Dale receives $765k base salary, 100% target bonus, and 600,000 PSUs tied to stock price goals and Avance Nerve Graft BLA approval.","Dale has 30+ years med device experience, most recently President of structural heart at Abbott (NYSE: ABT).","Zaderej remains in advisory role for nine months under a previously disclosed Transition and Separation Agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2120199958.4981904,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216422,"accession_number":"0000805928-24-000107","cik":805928,"company_name":"Axogen, Inc.","ticker":"AXGN","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Axogen Q2 revenue up 25.6% to $47.9M; net loss narrows; raises FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $47.9M (+25.6% YoY); net loss $1.9M ($0.04/share) vs $6.7M loss prior year.","Adjusted net income $2.0M ($0.05/share); adjusted EBITDA $5.6M vs loss $0.2M.","FY2024 revenue guidance raised to $182-186M; gross margin guidance adjusted to 74-76%.","Rolling BLA submission for Avance Nerve Graft initiated; expects completion Q3 2024, potential approval mid-2025.","Launched Avive+ Soft Tissue Matrix in June; Core accounts up 18.7% to 412."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":89289000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2120199958.4981904,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":235996,"accession_number":"0001193125-24-157679","cik":805928,"company_name":"Axogen, Inc.","ticker":"AXGN","form_type":"8-K/A","filed_at":"2024-06-10T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Axogen shareholders elect all nine directors, approve LTIP share increase to 10.5M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All nine director nominees elected; broker non-votes 4,270,312 on each proposal.","Ratification of Deloitte as auditor: 35,220,045 for, 1,254,727 against.","Advisory say-on-pay approved: 22,655,899 for, 9,494,316 against.","Third amended 2019 LTIP approved; shares increased from 8M to 10.5M: 22,846,399 for, 9,336,789 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.15,"market_cap_usd":2120199958.4981904,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":235998,"accession_number":"0000805928-24-000079","cik":805928,"company_name":"Axogen, Inc.","ticker":"AXGN","form_type":"8-K","filed_at":"2024-06-07T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Axogen shareholders vote down proposal to increase LTIP share reserve; Freitag departs board","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gregory Freitag not re-nominated; Board accelerated vesting of 11,904 RSUs and options for 20,436 shares.","All nine director nominees elected; average 'For' votes ~27.4M vs ~4.6M withheld.","Ratification of Deloitte as auditor approved (35.2M for, 1.3M against, 20k abstain).","Advisory say-on-pay approved (22.7M for, 9.5M against, 74k abstain).","Proposal to increase LTIP shares from 8M to 10.5M failed (22.8M for, 9.3M against, 41k abstain)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":2120199958.4981904,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":235997,"accession_number":"0000805928-24-000070","cik":805928,"company_name":"Axogen, Inc.","ticker":"AXGN","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Axogen Q1 2024 revenue $41.4M (+12.9% YoY); net loss narrows to $6.6M; adj EBITDA turns positive","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $41.4M, up 12.9% YoY; gross margin improved to 78.8% from 77.7%.","Net loss $6.6M ($0.15/sh) vs $7.1M ($0.17/sh) in Q1 2023; adjusted net loss $2.7M ($0.06/sh).","Adjusted EBITDA positive at $1.0M vs loss of $3.8M in prior year.","Cash & investments $23.6M as of March 31, 2024, down from $37.0M at Dec 31, 2023.","Reaffirmed FY2024 revenue guidance $177M-$181M; gross margin 76%-79%; expects positive net cash flow Apr-Dec 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":41378000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2120199958.4981904,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}